Studies have shown an increasing trend in plasma and CSF GFAP levels in dogs with CCDS, which supports its potential use as part of a biomarker panel [ 15 , 43 ].
← all excerpts
Evidence-Based Clinical Management of Canine Cognitive Dysfunction Syndrome: Diagnostic Algorithms, Practical Guidelines, Critical Appraisal of Biomarkers and Translational Limitations.
1
—
—